Certara (CERT) Expected to Announce Earnings on Thursday

Certara (NASDAQ:CERT) will likely be posting its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $104.53 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The company had revenue of $104.57 million during the quarter, compared to analyst estimates of $104.14 million. During the same period in the prior year, the business earned $0.07 EPS. The business’s revenue for the quarter was up 12.1% on a year-over-year basis. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Price Performance

CERT opened at $11.58 on Thursday. The company has a fifty day moving average price of $11.75 and a two-hundred day moving average price of $11.64. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. Certara has a 52 week low of $8.64 and a 52 week high of $15.69. The firm has a market capitalization of $1.86 billion, a PE ratio of 231.65 and a beta of 1.45.

Insider Buying and Selling at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total transaction of $559,366.08. Following the transaction, the insider directly owned 73,979 shares of the company’s stock, valued at $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.33% of the stock is owned by insiders.

Hedge Funds Weigh In On Certara

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wasatch Advisors LP lifted its holdings in shares of Certara by 45.7% in the 2nd quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock worth $158,335,000 after acquiring an additional 4,244,230 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Certara by 27.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after buying an additional 1,165,064 shares during the last quarter. Invesco Ltd. raised its holdings in Certara by 33.0% during the 2nd quarter. Invesco Ltd. now owns 523,965 shares of the company’s stock valued at $6,130,000 after buying an additional 129,928 shares during the last quarter. First Trust Advisors LP raised its holdings in Certara by 3,000.6% during the 2nd quarter. First Trust Advisors LP now owns 394,924 shares of the company’s stock valued at $4,621,000 after buying an additional 382,187 shares during the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in Certara by 8.3% during the 2nd quarter. Public Sector Pension Investment Board now owns 376,100 shares of the company’s stock valued at $4,400,000 after buying an additional 28,924 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Analyst Ratings Changes

CERT has been the topic of several research reports. KeyCorp boosted their price objective on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Morgan Stanley initiated coverage on shares of Certara in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Certara in a report on Wednesday, October 8th. Barclays upped their price target on shares of Certara from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Finally, Craig Hallum began coverage on shares of Certara in a research report on Monday, September 29th. They set a “buy” rating and a $16.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.63.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.